On May 21, 2021 Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, reported its collaboration with the American Skin Association to provide a 2021 research grant in the area of melanoma (Press release, Castle Biosciences, MAY 21, 2021, View Source [SID1234580452]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The ASA Castle Biosciences Research Grant Melanoma was awarded to Joel Sunshine, M.D., Ph.D., assistant professor at The Johns Hopkins University School of Medicine. The grant will support Dr. Sunshine’s research study entitled "mRNA Nanoparticle Vaccination for Melanoma Immunotherapy."
"These crucial grants in support of cutting-edge dermatological research will improve the chances of finding long sought-after cures and bring hope to those suffering from these devastating illnesses," said ASA Chairman, Howard P. Milstein.
"At Castle, our main focus is to improve the lives of patients with dermatologic diseases," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "We are proud to recognize and support research in new technology that stands to make meaningful advances in the area of skin cancer. Melanoma remains largely unexplored with respect to the disease’s behavior in response to targeted immunotherapies. With that in mind, we are thrilled to support Dr. Sunshine and his group in pursuing an immunotherapy approach to melanoma."
ASA’s grant program is steered by leading scientists and physicians to support talented researchers, ranging from talented investigators in the early phases of their careers to recognized leaders in the field of dermatology. In particular, ASA-funded researchers have had a broad impact on melanoma research, improving our understanding of its diagnosis, treatment and prognosis. For over thirty years, ASA and its affiliates have funded over $50 million in grants to enhance treatments and continue working toward cures for melanoma, vitiligo, psoriasis, atopic dermatitis and other skin diseases.